New treatments of ANCA-associated vasculitis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 17, Issue 2, 2000, Pages 125-129

  Kallenberg, Cees G M ^a   Cohen Tervaert, Jan W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti neutrophil cytoplasmic antibodies; Systemic vasculitis; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

HUMAN; MAINTENANCE THERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; SURVIVAL TIME; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 0034125382     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW: Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15.
3. Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-8
4. Hoffman GS, Kerr GS, Leavitt KY, et al: Wegener's Granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
5. Westman KWA, Bygren PG, Olssen H, Romstam J, Wieslander J: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangijtis with renal involvement. J Am Soc Nephrol 1998; 9: 842-52.
6. Rasmussen N, Jayne DRW: Review of the activities of the European Vasculitis Study Group. Clin Exp Immunol 1998; 112 (suppl 1): 13-15.
7. Luqmani RA, Exley A, Kitas G, Bacon PA: Disease assessment and management of the vasculitides. Baillières Clin Rheumatol 1997; 11: 423-6.
8. Pusey CD, Recs AJ, Evans DJ, Peters DK, Lockwood CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-63.
9. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive nephritis. Am J Nephrol 1989; 9: 368-75.
10. Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337: 1137-9.
11. Lockwood CM: New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996; 104 (suppl 1): 77-82.
12. Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD: Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83: 298-303.
13. Mathieson PW, Oliveira DBG: The role of cellular immunity in systemic vasculitis. Clin Exp Immunol 1995; 100: 183-5.
14. Tipping PG, Kitching AR, Cunningham MA, Holdsworth SR: Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens 1999; 8: 281-6.
15. Hagen EC, de Keizer RJW, Andrassy K, et al: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995; 43: 351-9.
16. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341: 1620-2.
17. Passweg J, Gratwohl A, Tyndall A. Hematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol 1999; 6: 400-5.
18. Wulfraat N, van Royen A, Bierrings M, Vossen J, Kuis W: Autologous haemopoictic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 13: 550-3.
19. Bradley JD, Brandt KD, Katz BP: Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53.
20. Stillwell ThJ, Benson RC, DeRemee RA, McDonald ThJ, Weiland LH: Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 465-70.
21. Balow JE, Austin HA, Tsokos CG, Antonovych TT, Steinberg AD, Klippel JH: Lupus nephritis. Ann Intern Med 1987; 106: 79-94.
22. Hoffman GS, Leavitt RY, Fleisher THA, Minor JR, Fauci AS: Treatment of Wegener's Granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-10.
23. Adu D, Pall A, Luqmani RA, et al: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997; 90: 401-9
24. Gayraud M, Guillevin L, Cohen P, et al: Treatment of good-prognosis polyarteritis nodosa and Churg Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol 1997; 36: 1290-7.
25. Haubitz M, Schellong S, Gobel U, et al: Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective randomized study. Arthritis Rheum 1998; 41: 1835-44.
26. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322-9.
27. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
28. De Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL: Induction of remission in Wegener's Granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-5.
29. Stone JH, Tun W, Hellman DB: Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134-9.
30. Sandbom WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999; 5: 119-133.
31. Maini R, St. Clair EW, Breedveld F, et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-9.
32. Luqmani R, Jayne D: A multi-centre randomized trial of cyclophosphamide versus azathioprin during remission in ANCA-associated systemic vasculitis (CYCAZAREM). Arthritis Rheum 1999; 42: S225.
33. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, Van der Woude FJ: Mycophenolate mofetil for maintenance therapy in Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-71.
34. Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13: 2074-6.
35. Stegeman CA, Cohen Tervaert JW, Manson WL, Kallenberg CGM: Chronic nasal carriage of Staphylococcus aureus in Wegener's Granulomatosis: identification of a subgroup more prone to relapses. Ann Intern Med 1994; 120: 12-17.
36. Cohen Tervaert JW, Popa ER, Bos NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 1999: 11: 24-33.
37. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM: Trimethoprim-sulfamethoxazole for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996; 335: 16-20.
38. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al: Association between active Wegener's Granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149: 2461-5.
39. Boomsma MM, Stegeman CA, van der Leij M, et al: Prediction of relapses in Wegener's granulomatosis by measurement of anti neutrophil cytoplasmic antibody levels: a prospective study. Clin Exp Immunol 2000; in press.
40. Cohen Tervaert JW, Huitema MG, et al: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11.